Rite Aid Corporation (RAD) is a Medical - Pharmaceuticals company in the Healthcare sector, currently trading at $0.65. It has a SharesGrow Score of 36/100, indicating a weak investment profile with 1 out of 7 criteria passed.
Analyst consensus target is RAD = $7 (+979.7% upside).
Financials: revenue is $24.1B, +3.3%/yr average growth. Net income is $750M (loss), growing at -132.9%/yr. Net profit margin is -3.1% (negative). Gross margin is 19.9% (-1.7 pp trend).
Balance sheet: total debt is $5.8B with negative equity of -$642M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 1.21 (adequate). Debt-to-assets is 77.3%. Total assets: $7.5B.
Analyst outlook: 3 / 10 analysts rate RAD as buy (30%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 30/100 (Fail), Past 0/100 (Fail), Health 25/100 (Fail), Moat 34/100 (Fail), Future 52/100 (Partial), Income 10/100 (Fail).
